Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thermo Fisher Scientific's Current Accrued Expense for the quarter that ended in Jun. 2026 was R$28,270 Mil.
Thermo Fisher Scientific's quarterly Current Accrued Expense
declined
from Dec. 2025 (R$29,046 Mil) to Mar. 2026 (R$27,502 Mil) but then
increased
from Mar. 2026 (R$27,502 Mil) to Jun. 2026 (R$28,270 Mil).
Thermo Fisher Scientific's annual Current Accrued Expense
increased
from Dec. 2023 (R$23,725 Mil) to Dec. 2024 (R$31,646 Mil) but then
declined
from Dec. 2024 (R$31,646 Mil) to Dec. 2025 (R$29,046 Mil).
Thermo Fisher Scientific Current Accrued Expense Related Terms
Thermo Fisher Scientific Current Accrued Expense Historical Data
* Premium members only.
The historical data trend for Thermo Fisher Scientific's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific Current Accrued Expense Chart
Thermo Fisher Scientific Current Accrued Expense Calculation
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of R$28,270 Mil mean?
Thermo Fisher Scientific (BSP:TMOS34) has a Current Accrued Expense of R$28,270 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Thermo Fisher Scientific and its competitors.
Is Thermo Fisher Scientific's Current Accrued Expense too high?
Thermo Fisher Scientific's current Current Accrued Expense is R$28,270 Mil. Overall, Thermo Fisher Scientific has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Current Accrued Expense compare to DHR and IDXX?
Thermo Fisher Scientific's Current Accrued Expense of R$28,270 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Thermo Fisher Scientific and its competitors. Thermo Fisher Scientific's current Current Accrued Expense is R$28,270 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$62.78, compared to a current price of R$60.36 — trading 3.9% below its estimated fair value. The current Current Accrued Expense is R$28,270 Mil. Thermo Fisher Scientific's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Current Accrued Expense is R$28,270 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$60.36 is trading 3.9% below its estimated GF Value™ of R$62.78.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
Current Accrued Expense: R$28,270 Mil
GF Value™: R$62.78 vs. price of R$60.36 (3.9% below fair value)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
76GF Score
Get the complete analysis for BSP:TMOS34
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
